Rapport Therapeutics (NASDAQ:RAPP) Trading Down 10.5% – What’s Next?

Rapport Therapeutics (NASDAQ:RAPP)’s stock price dropped 10.5% during mid-day trading on Thursday . The company traded as low as $24.03 and last traded at $24.03. Approximately 36,385 shares traded hands during trading, a decline of 78% from the average daily volume of 166,587 shares. The stock had previously closed at $26.84.

Rapport Therapeutics Stock Performance

The business’s fifty day moving average is $21.79.

Rapport Therapeutics (NASDAQ:RAPP) last posted its earnings results on Thursday, August 8th. The company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($1.02). As a group, research analysts predict that Rapport Therapeutics will post -3.46 earnings per share for the current fiscal year.

Institutional Trading of Rapport Therapeutics

A number of large investors have recently made changes to their positions in RAPP. Values First Advisors Inc. purchased a new position in shares of Rapport Therapeutics during the third quarter worth approximately $31,000. SG Americas Securities LLC purchased a new stake in shares of Rapport Therapeutics in the third quarter valued at about $101,000. Logos Global Management LP acquired a new stake in shares of Rapport Therapeutics during the second quarter worth about $4,859,000. Perceptive Advisors LLC purchased a new position in shares of Rapport Therapeutics during the second quarter worth about $17,403,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Rapport Therapeutics in the 2nd quarter valued at about $1,757,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.